Navigation Links
Rising Burden of Diseases Drives the Pharmaceutical Industry in East Africa, Says Frost & Sullivan
Date:8/16/2010

CAPE TOWN, South Africa, Aug. 16 /PRNewswire/ -- Infectious diseases are rampant in sub-Saharan Africa. Urbanisation and westernised lifestyles have further increased the prevalence of non-communicable diseases such as cancer. The strong correlation between infectious diseases and cancer has additionally fuelled the incidence rates of various cancers, driving the pharmaceutical industry in key east African countries.

(Logo: http://photos.prnewswire.com/prnh/20081117/FSLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

"Although the management and prevention of infectious diseases has been the priority in sub-Saharan Africa, there is scant attention towards rising lifestyle diseases," says Frost & Sullivan programme manager Lizelle Wentzel. "For example, Uganda has one cancer institute, three oncologists and limited funding, but is attempting to make a difference through research collaborations, funding programmes, and training of staff to control the spread of cancer in the country."

New analysis from Frost & Sullivan (http://www.pharma.frost.com), The Pharmaceutical Industry in Key East African Countries, finds that the market earned revenues of $1.2 million in 2009 and estimates this to reach $2.8 million in 2016. The products covered in this study span the cardiovascular, respiratory, central nervous system, anti-infectives, oncology and diabetes sectors.

If you are interested in more information on this study, please send an e-mail to Patrick Cairns, Corporate Communications, at patrick.cairns@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

"Realising the growing burden of cancer has sparked increasing amounts of funding by private organisations and donors," says Wentzel. "East Africa has some of the highest rates of cancer in children and adults worldwide, with Uganda ranking first in the region."

Compounded by the spread of human immunodeficiency virus (HIV), cancer rates have risen to more than 20,000 fold in many African regions. Infectious diseases cause six of the ten most common cancers in Uganda. Kaposi sarcoma (KS) is the most widespread, with 975 new adult cases and 42 new child cases per annum. Nearly one in two Ugandans is infected with the human herpesvirus-8 (HHV-8).

However, access to inexpensive chemotherapy is limited, with most patients either not receiving any treatment or only a single course of drugs. Therefore, the survival rate of cancer patients post diagnosis is dismal in Uganda. Most patients cannot afford transport costs and treatment. While treatment is supposed to be free at the Ugandan Cancer Institute (UCI), the cost of a course of the recommended medication is $450.00. The lack of government support in cancer treatment curbs the successful management of this disease.

"The UCI's bed capacity is far below the demand and the institute requires a budget that far exceeds that of the Mulago Teaching Hospital's total annual budget for operation, salaries, education and awareness campaigns, and most importantly procurement of drugs," explains Wentzel.

Greater awareness about cancer and access to treatment is essential in alleviating the disease burden in Sub-Saharan Africa.

"The Ugandan government should recognise cancer as a priority disease and focus a percentage of annual funding towards the management of this disease," concludes Wentzel. "Although donor funding will alleviate some of the strain, it is crucial for the country to have access to anti-cancer treatments."

The Pharmaceutical Industry in Key East African Countries is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: Healthcare industry in Namibia, Pharmaceutical industry in Botswana, Healthcare regulatory environment in SADC, and Healthcare industry in Ghana. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & SullivanFrost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.The Pharmaceutical Industry in Key East African CountriesM57CContact:Patrick CairnsCorporate Communications – AfricaP: +27 18 464 2402E: patrick.cairns@frost.comhttp://www.frost.com
'/>"/>

SOURCE Frost & Sullivan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Roches Quinn Honored as 2010 HBA Rising Star
2. Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly
3. Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers
4. New Analysis Shows Troubling Trend in Triglyceride Levels May Be Linked to Rising Rates of Obesity
5. Studies Report Nocturia Was Associated With Risk of Death and Represented a Significant Economic Burden to U.S. Society
6. MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
7. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
8. New Global Survey Exposes Considerable Burden of Fibromyalgia Including Potential Economic Impact
9. PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
10. European Research Project Aims to Improve the Diagnosis and Therapy of Brain Diseases
11. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... LONDON , Dec. 8, 2016 ... This report on the global interventional radiology market ... market. The report comprises an elaborate executive summary, ... of various segments and sub-segments. The research ... Primary research formed the bulk of our research ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 KEY ... for the largest share of the market in 2016 ... This dominance can be attributed to a large number ... region. (US hold the largest share in the patient ... several benefits such as reducing loss of blood during ...
(Date:12/8/2016)... , Dec. 8, 2016 Allergy ... includes products and tests that are used to ... weed, peanuts, milk, or drugs etc. in the ... by the immune system. The report on global ... prospects of the market. The report consists of ...
Breaking Medicine Technology:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... The ... Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits and ... the District of Columbia as an education tool in the war against teen drug ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of fully-automated ... new solution for Emergency Departments (ED) has been added to their portfolio. Housed ... examination rooms, and with a simplified pallet of information available to the patient, ...
(Date:12/8/2016)... ... 2016 , ... After enjoying record-breaking attendance at its last ... 33rd Annual Issues & Research Conference, March 2-3, 2017, at the Westin ... is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." 2016 ...
(Date:12/8/2016)... ... 08, 2016 , ... CURE Media Group, the nation’s leading digital and print ... Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President ... “CURE Media Group is honored to team up with Upstage Lung Cancer in order ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching ... innovative Unified Instance Manager architecture, meeting the needs of multichannel growth and ... the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, ...
Breaking Medicine News(10 mins):